MA-OLYMPUS
21.3.2017 14:02:07 CET | Business Wire | Press release
Olympus’ latest addition to the Vanta™ series of handheld XRF analyzers is optimized to help ensure compliance with the Restriction of Hazardous Substances Directive (RoHS) and local or international regulatory laws. Like every Vanta analyzer, this new model combines fast, accurate results with a durable design for maximum uptime and a lower cost of ownership.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170321005923/en/
Vanta analyzers provide on-the-spot chemical analysis to quickly scan for toxic metals like lead (Pb), cadmium (Cd), mercury (Hg), chromium (Cr) and bromine (Br) in consumer products such as toys, apparel, footwear and electronics to comply with RoHS regulations. Excellent sensitivity and repeatability enable Vanta analyzers to achieve low detection limits for reliable pass/fail results of regulated elements.
Vanta XRF analyzers are accepted as a screening tool when testing for compliance with the following global hazardous substance regulations and testing methods as part of a reasonable testing program:
- EU RoHS Directive (2011/65/EU)
- China RoHS Directive (RPCEP)
- Japan RoHS
- Korean RoHS Directive
- USA CPSIA (HR4040)
- USA Halogen Free Directive
- California Preposition 65
- USA CPSC-CH-E1002-08 SOP
Vanta analyzers are IP65 rated* for protection against dust and water and drop tested to military standards (MIL-STD-810 G) for greater uptime. Vanta analyzers also incorporate Olympus’ revolutionary new Axon™ technology, a breakthrough in XRF signal processing that utilizes ultra-low-noise electronics to deliver higher X-ray count rates per second and test-to-test repeatability. The analyzer’s lower limits of detection accommodate future compliance as regulations change over time. Other features include:
- Intuitive interface and responsive touch screen
- Optional Wi-Fi and Bluetooth® connectivity for fast data downloads
- Customizable home screen
Olympus’ newest Vanta analyzer combines durability, power and ease of use for testing consumer goods.
About Olympus
Olympus Corporation operates in industrial, medical, and consumer markets, specializing in optics, electronics, and precision engineering. Olympus is a world-leading manufacturer of innovative test and measurement solutions that are used in industrial and research applications ranging from aerospace, power generation, petrochemical, civil infrastructure, and automotive to consumer products.
For more information about Vanta handheld XRF analyzers and Olympus’ line of nondestructive testing products contact a sales representative or visit http://www.olympus-ims.com .
*M series analyzers are IP64 rated.
Vanta and Axon are trademarks of Olympus Corporation.
The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Olympus Corporation is under license.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170321005923/en/
Contact:
Media Contact:
Olympus Corporation
Michelle Wright,
781-419-3664
Michelle.Wright@olympus-ossa.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom